Phase II clinical study of high-dose toremifene in patients with advanced breast cancer.
Thirteen postmenopausal women with advanced local or metastatic breast cancer were treated with the antiestrogen toremifene at a daily dose of 200 mg. All patients had failed previous treatment with different types of endocrine therapy and/or cytotoxic drugs. Objective response was only seen in one patient. Treatment was usually well tolerated but in three cases the drug had to be withdrawn due to side effects.
Modig
H
H
Department of Oncology, Umeå University Hospital, Sweden.
Borgström
S
S
Nilsson
I
I
Westman
G
G
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004965:Estrogen Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D013629:Tamoxifen / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017312:Toremifene
D004965:Estrogen Antagonists; D013629:Tamoxifen; D017312:Toremifene